Compare · OGEN vs SBFM
OGEN vs SBFM
Side-by-side comparison of Oragenics Inc. (OGEN) and Sunshine Biopharma Inc. (SBFM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OGEN and SBFM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- SBFM is the larger of the two at $2.2M, about 2.5x OGEN ($890,518).
- SBFM has been more active in the news (5 items in the past 4 weeks vs 2 for OGEN).
- Company
- Oragenics Inc.
- Sunshine Biopharma Inc.
- Price
- -
- -
- Market cap
- $890,518
- $2.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NASDAQ
- IPO
- News (4w)
- 2
- 5
- Recent ratings
- 0
- 0
Oragenics Inc.
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. Its product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. The company has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and production of lantibiotics, a peptide antibiotic that are naturally produced in gram-positive bacteria. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Sunshine Biopharma Inc.
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Latest OGEN
- SEC Form 10-Q filed by Oragenics Inc.
- Oragenics Receives NYSE American Approval of Compliance Plan and Extension Through February 2028
- Oragenics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
- Oragenics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits
- Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
- SEC Form 10-Q filed by Oragenics Inc.
- SEC Form 4 filed by Chief Financial Officer Spencer John
- New insider Spencer John claimed ownership of 53 shares (SEC Form 3)
- Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
Latest SBFM
- SEC Form DEFA14A filed by Sunshine Biopharma Inc.
- SEC Form 10-Q filed by Sunshine Biopharma Inc.
- SEC Form DEF 14A filed by Sunshine Biopharma Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Sunshine Biopharma Inc.
- SEC Form DEF 14C filed by Sunshine Biopharma Inc.
- Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
- SEC Form PRE 14C filed by Sunshine Biopharma Inc.
- SEC Form 8-K filed by Sunshine Biopharma Inc.
- SEC Form 8-K filed by Sunshine Biopharma Inc.
- SEC Form 424B4 filed by Sunshine Biopharma Inc.